Literature DB >> 8099938

Syngeneic response to SJL follicular center B cell lymphoma (reticular cell sarcoma) cells is primarily in V beta 16+ CD4+ T cells.

V K Tsiagbe1, J Asakawa, A Miranda, R M Sutherland, Y Paterson, G J Thorbecke.   

Abstract

The growth of SJL B cell lymphomas (RCS, reticulum cell sarcoma) in vivo and in vitro is known to depend on cytokine production by RCS-responsive host CD4+ T cells. The high frequency of RCS responsive cells in normal SJL lymph nodes prompted us to prepare a set of 21 RCS-specific T cell hybridomas. Like normal SJL T cells, these hybridoma cells respond to RCS, but not to normal syngeneic B cells; produce IL-2, IL-4, and IL-5; and promote growth of RCS in gamma-irradiated syngeneic hosts. A superantigen-like stimulation by RCS cells was borne out by the fact that all the RCS-specific hybridomas used V beta 16 in their TCR. RCS cells did not stimulate I-As-restricted, V beta 17a+ KLH-specific, or V beta 1+ heme-specific hybridomas, but were excellent Ag presents for these cells. Preincubation of RCS cells with high concentrations of the KM core peptide (high affinity for I-As) did not interfere with the ability of RCS to stimulate RCS-specific hybridomas. The relative representation of mRNA for V beta 1, 4, 10, 15, 16, and 17a was evaluated in RNA extracted from normal SJL lymph node cells responding to Con A or to RCS cells. Only V beta 16 was specifically enriched in the response to RCS. Moreover, the degree of responsiveness to RCS cells in lymph node cells from F1 hybrids of SJL and I-E transgenic SJL mice, corresponds to the relative abundance of V beta 16 in mRNA, but not of V beta 17a mRNA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099938

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  In memorium G. Jeanette Thorbecke, 1929-2001.

Authors:  Vincent K Tsiagbe; Susan Zolla-Pazner; Richard Coico; Nicholas M Ponzio
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 2.  Virus-encoded superantigens.

Authors:  B T Huber; P N Hsu; N Sutkowski
Journal:  Microbiol Rev       Date:  1996-09

Review 3.  Superantigens related to B cell hyperplasia.

Authors:  N M Ponzio; V K Tsiagbe; G J Thorbecke
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  Revenge of the microbes. Superantigens of the T and B cell lineage.

Authors:  L Goodglick; J Braun
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

5.  Expression of mouse mammary tumor virus superantigen accelerates tumorigenicity of myeloma cells.

Authors:  M Umemura; W Wajjwalku; N Upragarin; T Liu; H Nishimura; T Matsuguchi; Y Nishiyama; G M Wilson; Y Yoshikai
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  The Emu-bcl-2 transgene enhances antigen-induced germinal center formation in both BALB/c and SJL mice but causes age-dependent germinal center hyperplasia only in the lymphoma-prone SJL strain.

Authors:  E A Secord; J M Edington; G J Thorbecke
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

Review 7.  Superantigens in human disease.

Authors:  A Bernal; T Proft; J D Fraser; D N Posnett
Journal:  J Clin Immunol       Date:  1999-05       Impact factor: 8.542

8.  Susceptibility to tumors induced by polyoma virus is conferred by an endogenous mouse mammary tumor virus superantigen.

Authors:  A E Lukacher; Y Ma; J P Carroll; S R Abromson-Leeman; J C Laning; M E Dorf; T L Benjamin
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

Review 9.  Endogenous mouse mammary tumor viruses (mtv): new roles for an old virus in cancer, infection, and immunity.

Authors:  Michael P Holt; Ethan M Shevach; George A Punkosdy
Journal:  Front Oncol       Date:  2013-11-26       Impact factor: 6.244

Review 10.  Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.

Authors:  Tyler A Herek; Christine E Cutucache
Journal:  Front Oncol       Date:  2017-05-02       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.